Menu

Medical

Novartis announces FDA Advisory Committee unanimously recommends approval of AIN457 (secukinumab) for patients with moderate-to-severe plaque psoriasis

,

Biologics License Application (BLA) for secukinumab, a “first-in-class” IL-17A inhibitor, is currently under FDA review with an anticipated action date in early 2015 FDA Advisory Committee recommendation based on efficacy and safety outcomes of 10 Phase II/III clinical studies of secukinumab in moderate-to-severe plaque psoriasis Affecting 7.5 million Americans, psoriasis may negatively impact daily life […]

US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine

,

Phase III clinical study data presented at IDWeek in Philadelphia October 20, 2014 – WHITEHOUSE STATION, N.J. & SWIFTWATER, Pa.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT:SAN and NYSE:SNY), announced today that the Biologics License Application (BLA) filed for the companies’ investigational […]

Celgene Participates in New Round of Investment for Sequenta

,

SOUTH SAN FRANCISCO, Calif. OCTOBER 20, 2014 – Sequenta, Inc., a biotechnology company developing clinical diagnostics based on immune cell receptor genes, today announced an equity investment by Celgene Corporation and other strategic investors. This financing, in addition to funding secured from several other strategic investors, will support incorporation of the ClonoSIGHT™ minimal residual disease […]

GE Healthcare’s latest innovations may help clinicians with more accurate, faster diagnosis and treatment

,

Gothenburg, Sweden – October 18, 2014 – GE Healthcare shares a suite of advances in imaging quantitation that may help clinicians diagnose disease earlier, deliver more personalised treatment and speed up care at the 27th annual meeting of the European Association of Nuclear Medicine (EANM), 18-22 October, in Gothenburg. Valérie Brissart, Europe Regional Marketing Director […]

GE Healthcare and Karolinska University Hospital in Sweden Partner to Improve the Treatment of Pelvic Cancer

,

The new care pathway for advanced pelvic cancer encourages knowledge transfer and multidisciplinary care Stockholm, Sweden – 17 October 2014 – GE Healthcare and Karolinska University Hospital in Stockholm, Sweden, have established a partnership to improve the efficiency of the care pathway for pelvic cancer patients and reduce unwarranted clinical variation. GE Healthcare will be […]

Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors

, ,

THOUSAND OAKS, Calif., Oct. 17, 2014 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced the appointment of R. Sanders Williams, M.D., president of Gladstone Institutes and Gladstone’s Robert W. and Linda L. Mahley Distinguished Professor. “We are pleased to welcome Dr. Sandy Williams to the Amgen Board,” said Robert A. Bradway, chairman and chief executive officer […]

FDA approves Esbriet (pirfenidone) for the treatment of idiopathic pulmonary fibrosis (IPF) in the United States

,

Approximately 100,000 people in the United States have IPF, an irreversible and fatal lung disease1 Esbriet approved under FDA’s breakthrough designation program Basel, 16 October 2014 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Esbriet (pirfenidone) as a treatment for idiopathic pulmonary fibrosis (IPF) […]

Sustainability at Work awards Silver Certification to Cambia Health Solutions

,

PORTLAND, OCTOBER 14, 2014 — Cambia Health Solutions has achieved Sustainability at Work’s silver certification in recognition of its leadership helping make Portland one of the cleanest, most sustainable cities in the country. To earn this honor, Cambia completed numerous sustainability actions, which were verified during an onsite visit with Sustainability at Work Advisors. “Cambia […]

U.S. Food and Drug Administration Approves Gilead’s Harvoni® (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C

, , ,

Harvoni Achieved Cure Rates (SVR12) of 94-99 Percent in Three Phase 3 Studies Shortens Treatment Duration to Just Eight Weeks for Certain Treatment-Naïve Patients Eliminates Need for Interferon and Ribavirin for Patients with Genotype 1 Hepatitis C FOSTER CITY, Calif.–(BUSINESS WIRE)–Oct. 10, 2014– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and […]

New Breast Cancer Screening Report Shows Many Women are Unaware that Dense Breast Tissue Masks Cancer and May Lead to Higher Risk

,

Low Level of Awareness Revealed About Breast Density and Lower Accuracy of Mammogram Screening for Dense Breasts NEW YORK, NY, October 8, 2014–A new survey entitled “Diagnosis Anxiety: The Working Mother Breast Screening Report” sheds important new information on the level of awareness women have about breast cancer today and what they are doing to […]

«‹ 27 28 29 30›»